Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 –…
Immunization with a protein-based immunogen, DYAI-100, a receptor binding domain (RBD) of SARS-CoV-2, resulted in potent B cell immunity in preclinical studies, with strong serological…